Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab prophylaxis in severe haemophilia A without inhibitors
2016-000614-29Phase 2Suspended
- Sponsor
- Novo Nordisk
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of concizumab in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of bleeding episodes. Started Jun 2017; status: suspended.
02
Drugs
concizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-000614-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000614-29.